Filing Flows

Filing Flows › Companies › Iradimed › Cash flow

Iradimed cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow$6.9M in Q3 2026 · $26.1M over twelve months

Operating cash flow$7.0M
Capital spending−$130K
Free cash flow+$6.9M
Cash / net income1.1×
Cash conversion cycle223 days

Analysis

In Q3 2026, Iradimed generated $7.0M of operating cash flow and spent $130K on capital projects, leaving free cash flow of $6.9M. That is $1.0M more than in Q3 2025 ($5.8M).

Over the twelve months to Sep 30, 2026, operating cash flow was $27.1M; the largest uses were dividends ($16.2M), taxes on employees’ shares ($2.6M), capital spending ($1.0M); the cash balance rose by $6.8M.

Operating cash flow was $7.0M against net income of $6.5M — 1.1× profit, roughly in line with earnings. The largest differences: inventory −$1.3M, stock-based pay +$777K, receivables −$593K.

Its cash conversion cycle was 223 days (receivables 51 + inventory 206 − payables 34).

Free cash flow

Iradimed: free cash flow by quarterIradimed: free cash flow by quarter$3.2MQ4 2024$595KQ1 2025$5.1MQ2 2025$5.8MQ3 2025$5.6MQ4 2025$7.9MQ1 2026$5.8MQ2 2026$6.9MQ3 2026
Operating cash flow less capital spending.
Iradimed: operating cash flow against capital spendingIradimed: operating cash flow against capital spendingOperating cash flowCapital spending$6.0M$2.8MQ4 2024$4.3M$3.7MQ1 2025$7.7M$2.6MQ2 2025$7.0M$1.1MQ3 2025$5.9M$294KQ4 2025$8.3M$403KQ1 2026$5.9M$185KQ2 2026$7.0M$130KQ3 2026
Latest (Q3 2026): Operating cash flow $7.0M, Capital spending $130K.

Capital allocation, year by year

Iradimed: where the cash came from (up) and went (down), by fiscal yearIradimed: where the cash came from (up) and went (down), by fiscal yearOperating cash flowShares issuedCapital spendingDividendsFY2021: Operating cash flow $11.3MFY2021: Shares issued $623KFY2021: Capital spending −$482K$11.9MFY2021FY2022: Operating cash flow $10.0MFY2022: Shares issued $147KFY2022: Capital spending −$823KFY2022: Dividends −$12.6M$10.2MFY2022FY2023: Operating cash flow $13.5MFY2023: Shares issued $177KFY2023: Capital spending −$7.4MFY2023: Dividends −$13.2M$13.6MFY2023FY2024: Operating cash flow $25.6MFY2024: Shares issued $29KFY2024: Capital spending −$8.0MFY2024: Dividends −$13.7M$25.7MFY2024FY2025: Operating cash flow $24.9MFY2025: Capital spending −$7.8MFY2025: Dividends −$15.0M$24.9MFY2025
Over these 5 years operating cash flow totalled $85.3M; the largest uses were dividends ($54.5M) and capital spending ($24.5M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$63.3M
Debtnone
Net cash$63.3M

Iradimed funds itself: free cash flow was $26.1M over the last twelve months, with $63.3M of cash and investments and no debt on the balance sheet.

Where the cash came from and went

Iradimed: sources (+) and uses (−) of cash, Q3 2026Iradimed: sources (+) and uses (−) of cash, Q3 2026Operating cash flow$7.0MCash drawn (+) / kept (−)−$4.2MDividends−$2.6MCapital spending−$130KOther investing−$82KTaxes on employees’ shares−$19K
Iradimed: sources (+) and uses (−) of cash, TTM to Q3 2026Iradimed: sources (+) and uses (−) of cash, TTM to Q3 2026Operating cash flow$27.1MDividends−$16.2MCash drawn (+) / kept (−)−$6.8MTaxes on employees’ shares−$2.6MCapital spending−$1.0MOther investing−$528K

From profit to cash

Iradimed: net income to operating cash flow, Q3 2026Iradimed: net income to operating cash flow, Q3 2026Net income$6.5MDepreciation & amortization$412KStock-based pay$777KGains on disposals$5KReceivables−$593KInventory−$1.3MPayables$570KEmployee-related liabilities$564KDeferred revenue$333KPrepaid and other assets$150KOperating cash flow$7.0M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q3 20265120634223
Q2 20265920735232
Q1 20265520535225
Q4 20255619034212
Q3 20255422441236
Q2 20255322246229
Q1 20255420243212
Q4 20245021533232

Every quarter

QuarterOperating cash flowCapital spendingDividendsShares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026$7.0M−$130K−$2.6M—−$4.2M$6.9M
Q2 2026$5.9M−$185K−$2.6M—−$2.7M$5.8M
Q1 2026$8.3M−$403K−$2.6M—−$5.2M$7.9M
Q4 2025$5.9M−$294K−$8.6M—$5.4M$5.6M
Q3 2025$7.0M−$1.1M−$2.2M—−$3.5M$5.8M
Q2 2025$7.7M−$2.6M−$2.2M—−$2.7M$5.1M
Q1 2025$4.3M−$3.7M−$2.2M—$1.9M$595K
Q4 2024$6.0M−$2.8M−$1.9M$26K−$513K$3.2M

Iradimed: income statement and cash flow

Iradimed, Q3 2026: revenue $24.2M (+14% year over year), operating margin 33.6%. The chart follows the revenue to costs, profit and cash.

Iradimed: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.